Meeting
2022 ASCO Annual Meeting
Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy: A single-center, single-arm, prospective phase 2 study.
Authors
Chunfang Hao
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Chunfang Hao , Xu Wang , Yehui Shi , Zhongsheng Tong , Shufen Li , Xiaodong Liu , Lan Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT04903652.
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1033)
DOI
10.1200/JCO.2022.40.16_suppl.1033
Abstract #
1033
Poster Bd #
411
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
First Author: Ahmad Awada
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.
First Author: Tae-Yong Kim
Poster
2022 ASCO Annual Meeting
A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).
First Author: Jianming Xu
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan